CLINICAL RESEARCH
Gastrointestinal and Endocrine Tumors Group

JOSEP TABERNERO

JOSEP TABERNERO
Director
Biosketch

STRATEGIC GOALS

  • Clinical research in late stage with more translational endpoints, focusing on the identification of prognostic/predictive markers
  • Discovery of novel biomarkers in gastrointestinal tumorigenesis.
  • Validation of new prognostic biomarkers.
  • Development of relevant preclinical models in vitro and in vivo with emphasis on the identification of predictive markers.
  • Molecular characterization of major diseases, with particular focus on colorectal cancer, in different targetable subtypes.
  • Early clinical research with innovative targets.
  • Clinical research in late stage with more translational endpoints, focusing on the identification of prognostic/predictive biomarkers.
  • Design of increased participation in novel Basket trials.
  • Participation in multidisciplinary/multinational consortia and collaborative research programs of excellence.
  • Validation of repurposed drugs or candidate drugs, in partnership with pharma companies or academic groups.
  • Expansion of our collaboration with other VHIO teams (Proteomics, Tumor Biomarkers, Cancer Genomics, Translational Genomics, and Stem Cells & Cancer Groups).

CURRENT OBJECTIVES

  • Development of strategies to identify populations of patients
  • Development of strategies to identify populations of patients
  • Preclinical and clinical development of new drugs targeting different cancer properties.
  • Identification of Molecular Markers in Gastrointestinal Malignancies
  • Circulating Tumor Cells (CTCs) and Circulant DNA (cDNA) to develop prognostic and predictive biomarkers, with special emphasis on filtration collection techniques
  • Continued participation in international consortia of excellence as well as cooperative and singular research projects aligned with our group´s research objectives

TEAM

  • Director, Josep Tabernero
  • Principal Investigator
    • Teresa Macarulla
  • Medical Oncologists and Clinical Research Fellows
    • Maria Alsina
    • Guillem Argilés
    • Jaume Capdevila
    • María Elena Élez
    • Jorge Hernando
    • Ignacio Matos
    • Nuria Mulet
    • Alba Noguerido
    • Fabricio Eugenio Racca
    • Helena Verdaguer
  • Translational Investigator
    • Rodrigo A. Toledo
  • Clinical Nurse Specialist
    • Ariadna García
  • Masters Student
    • Giulia Martini
  • Bioinformatician
    • Pol Cusco

Most relevant scientific publications

  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 Dec 15;358(6369):1443-1448.
  • Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herráez-Baranda LA, Xia F, Garg A, Shing M, Tabernero J. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in PatientsWith Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. J Clin Oncol. 2017 Aug 1;35(22):2558-2567.
  • Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol. 2017 May 1;3(5):620-627.
  • Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-TypeMetastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017 3:194-201.
  • Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57.
  • Martínez-Cardús A, Moran S, Musulen E, Moutinho C, Manzano JL, Martinez-Balibrea E, Tierno M, Élez E, Landolfi S, Lorden P, Arribas C, Müller F, Bock C, Tabernero J, Esteller M. Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology. 2016 Nov;151(5):961-972.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P , Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56.
  • Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Mol Cancer Ther. 2016 May;15(5):1106-12.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG.  Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Kubicka S.  [Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial].Strahlenther Onkol 2016 Jul; 192(7): 505-6
  • Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.  First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol 2016 Apr; 11(2): 149-56
  • Dienstmann R, Rodón J, Tabernero J.  Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 2015 May; 9(5): 940-50
  • Alsina M, Landolfi S, Aura C, Caci K, Jimenez J, Prudkin L, Castro S, Moreno D, Navalpotro B, Tabernero J, Scaltriti M.  Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann. Oncol. 2015 Feb; 26(2): 438-9

All publications

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T; ALEX Trial Investigators.2017.N Engl J Med.377: 829-838. IF:72,406
  • CANCER A precision approach to tumour treatment. Dienstmann, Rodrigo; Tabernero, Josep. 2017.Nature.548: 40-41. IF:40,137
  • mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Zabala-Letona A; Arruabarrena-Aristorena A; Martín-Martín N; Fernandez-Ruiz S; Sutherland JD; Clasquin M; Tomas-Cortazar J; Jimenez J; Torres I; Quang P; Ximenez-Embun P; Bago R; Ugalde-Olano A; Loizaga-Iriarte A; Lacasa-Viscasillas I; Unda M; Torrano V; Cabrera D; van Liempd SM; Cendon Y; Castro E; Murray S; Revandkar A; Alimonti A; Zhang Y; Barnett A; Lein G; Pirman D; Cortazar AR; Arreal L; Prudkin L; Astobiza I; Valcarcel-Jimenez L; Zuñiga-García P; Fernandez-Dominguez I; Piva M; Caro-Maldonado A; Sánchez-Mosquera P; Castillo-Martín M; Serra V; Beraza N; Gentilella A; Thomas G; Azkargorta M; Elortza F; Farràs R; Olmos D; Efeyan A; Anguita J; Muñoz J; Falcón-Pérez JM; Barrio R; Macarulla T; Mato JM; Martinez-Chantar ML; Cordon-Cardo C; Aransay AM; Marks K; Baselga J; Tabernero J; Nuciforo P; Manning BD; Marjon K; Carracedo A.2017.Nature.547: 109-0. IF:40,137
  • Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Bullman, Susan; Pedamallu, Chandra S.; Sicinska, Ewa; Claney, Thomas E.; Zhang, Xiaoyang; Cai, Diana; Neuberg, Donna; Huang, Katherine; Guevara, Fatima; Nelson, Timothy; Chipashvili, Otari; Hagan, Timothy; Walker, Mark; Ramachandran, Aruna; Diosdado, Begona; Serna, Garazi; Mulet, Nuria; Landolfi, Stefania; Ramon y Cajal, Santiago; Fasani, Roberta; Aguirre, Andrew J.; Ng, Kimmie; Elez, Elena; Ogino, Shuji; Tabernero, Josep; Fuchs, Charles S.; Hahn, William C.; Nuciforo, Paolo; Meyerson, Matthew. 2017.Science.358: 1443-0. IF:37,205
  • Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Dienstmann R; Vermeulen L; Guinney J; Kopetz S; Tejpar S; Tabernero J. 2017.Nat Rev Cancer.17: 79-92. IF:37,147
  • The Cancer Moonshot from a European perspective.Ciardiello F; Tabernero J. 2017.Lancet Oncol.18: 626-0. IF:33,900
  • Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study.Ott, P.A.; Elez, E.; Hiret, S.; Kim, D.-W.; Morosky, A.; Saraf, S.; Piperdi, B.; Mehnert, J.M.. 2017.J Clin Oncol.35: 3823-3829. IF:24,008
  • Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study.Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC. 2017.J Clin Oncol.35: 2535-2541. IF:24,008
  • HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma.Shah MA; Xu RH; Bang YJ; Hoff PM; Liu T; Herráez-Baranda LA; Xia F; Garg A; Shing M; Tabernero J. 2017.J Clin Oncol.35: 2558-2567. IF:24,008
  • Targeting c-MET in gastrointestinal tumours: Rationale, opportunities and challenges. Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S; MErCuRIC consortium. 2017.Nat Rev Clin Oncol.14: 562-576. IF:20,693
  • A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors. Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A. 2017.Cancer Discov.7: 102-113. IF:20,011
  • A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. van Geel RM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema M; Faris JE; Eskens FA; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JH. 2017.Cancer Discov.7: 610-619. IF:20,011
  • Improving the armamentarium of PI3K inhibitors with isoform-selective agents: A new light in the darkness.Rodon J; Tabernero J.2017.Cancer Discov.7: 666-669. IF:20,011
  • Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.Tejpar, Sabine; Stintzing, Sebastian; Ciardiello, Fortunato; Tabernero, Josep; Van Cutsem, Eric; Beier, Frank; Esser, Regina; Lenz, Heinz-Josef; Heinemann, Volker. 2017.JAMA Oncol.3: 194-201. IF:16,559
  • Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial.Shah MA; Bang YJ; Lordick F; Alsina M; Chen M; Hack SP; Bruey JM; Smith D; McCaffery I; Shames DS; Phan S; Cunningham D. 2017.JAMA Oncol.3: 620-627. IF:16,559
  • Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer..Taieb J; Le Malicot K; Shi Q; Penault Lorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Francois Emile J; Laurent Puig P; Sinicrope FA. 2017.J Natl Cancer Inst.IF:12,589
  • Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: Do we need to worry?.Font R; Espinas JA; Layos L; Martinez Villacampa M; Capdevila J; Tobeña M; Pisa A; Pericay C; Lezcano C; Fort E; Cardona I; Berga N; Solà J; Borras JM. 2017.Ann Oncol.28: 831-835. IF:11,855
  • Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients..Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P; for PETACC8 investigators. 2017.Ann Oncol.28: 824-830. IF:11,855
  • Intratumoral heterogeneity in gastric cancer: a new challenge to face..Alsina M; Gullo I; Carneiro F. 2017.Ann Oncol.28: 912-913. IF:11,855
  • A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial..Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC. 2017.Ann Oncol.28: 1309-1315. IF:11,855
  • Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A. 2017.Ann Oncol.28: 1294-1301. IF:11,855
  • Targeting the fibroblast growth factor receptor 2 in gastric cancer: Promise or pitfall? Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J. 2017.Ann Oncol.28: 1207-1216. IF:11,855
  • Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Banerjee S; Califano R; Corral J; de Azambuja E; De Mattos-Arruda L; Guarneri V; Hutka M; Jordan K; Martinelli E; Mountzios G; Ozturk MA; Petrova M; Postel-Vinay S; Preusser M; Qvortrup C; Volkov MNM; Tabernero J; Olmos D; Strijbos MH. 2017.Ann Oncol.28: 1590-1596. IF:11,855
  • Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio. Cherny NI; Dafni U; Bogaerts J; Pentheroudakis G; Tabernero J; Zielinski C; de Vries EGE. 2017.Ann Oncol.28: 2031-2032. IF:11,855
  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F. 2017.Ann Oncol.28: 1713-1729. IF:11,855
  • Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies. Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M. 2017.Ann Oncol.28: 1862-1868. IF:11,855
  • Reply to the letter to the editor ‘Can we trust burnout research?’ by Bianchi et al. Banerjee S; Preusser M; Tabernero J; Strijbos M. 2017.Ann Oncol.28: 2625-2626. IF:11,855
  • ESMO-Magnitude of Clinical Benefit Scale version 1.1.Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE. 2017.Ann Oncol.28: 2340-2366. IF:11,855
  • BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Sanz-Garcia E; Argiles G; Elez E; Tabernero J. 2017.Ann Oncol.28: 2648-2657. IF:11,855
  • Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Arnold D; Fuchs C; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I. 2017.Ann Oncol.28: 2932-2942. IF:11,855
  • DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time? Páez D; Salazar R; Tabernero J. 2017.Ann Oncol.28: 2913-2914. IF:11,855
  • A first-in-human, Phase I, dose-escalation study of TAK-117, A selective PI3Ka isoform inhibitor, in patients with advanced solid malignancies. Juric D; de Bono JS; LoRusso PM; Nemunaitis J; Heath EI; Kwak EL; Macarulla Mercadé T; Geuna E; Jose de Miguel-Luken M; Patel C; Kuida K; Sankoh S; Westin EH; Zohren F; Shou Y; Tabernero J. 2017.Clin Cancer Res.23: 5015-5023. IF:9,619
  • Strategies to design clinical studies to identify predictive biomarkers in cancer research. Perez-Gracia JL; Sanmamed MF; Bosch A; Patiño-Garcia A; Schalper KA; Segura V; Bellmunt J; Tabernero J; Sweeney CJ; Choueiri TK; Martín M; Fusco JP; Rodriguez-Ruiz ME; Calvo A; Prior C; Paz-Ares L; Pio R; Gonzalez-Billalabeitia E; Gonzalez Hernandez A; Páez D; Piulats JM; Gurpide A; Andueza M; de Velasco G; Pazo R; Grande E; Nicolas P; Abad-Santos F; Garcia-Donas J; Castellano D; Pajares MJ; Suarez C; Colomer R; Montuenga LM; Melero I.2017.Cancer Treat Rev.53: 79-97. IF:8,589
  • The expanding role of immunotherapy. Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J. 2017.Cancer Treat Rev.54: 74-86. IF:8,589
  • Translational research in neuroendocrine tumors: Pitfalls and opportunities. Capdevila J; Casanovas O; Salazar R; Castellano D; Segura A; Fuster P; Aller J; García-Carbonero R; Jimenez-Fonseca P; Grande E; Castaño JP. 2017.Oncogene.36: 1899-1907. IF:7,519
  • Pancreatic cancer heterogeneity and response to Mek inhibition. Pedersen K; Bilal F; Bernadó Morales C; Salcedo MT; Macarulla T; Massó-Vallés D; Mohan V; Vivancos A; Carreras MJ; Serres X; Abu-Suboh M; Balsells J; Allende E; Sagi I; Soucek L; Tabernero J; Arribas J.2017.Oncogene.36: 5639-5647. IF:7,519
  • Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ. 2017.INT J CANCER.140: 431-439. IF:6,513
  • Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Sclafani F; Brown G; Cunningham D; Wotherspoon A; Mendes LST; Balyasnikova S; Evans J; Peckitt C; Begum R; Tait D; Tabernero J; Glimelius B; Roselló S; Thomas J; Oates J; Chau I. 2017.Br J Cancer.117: 1478-1485. IF:6,176
  • Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J. 2017.Eur J Cancer.78: 61-69. IF:6,029
  • Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Emile JF; Julié C; Le Malicot K; Lepage C; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenn; Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD); Gruppo Oncologico dell’Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação; Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater. 2017.Eur J Cancer.82: 16-24. IF:6,029
  • Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer. Santos C; Azuara D; Garcia-Carbonero R; García Alfonso P; Carrato A; Elez E; Gómez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; López-Doriga A; Moreno V; Valladares M; Manzano JL; Viéitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R. 2017.Mol Cancer Ther.16: 1999-2007. IF:5,764
  • Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Tabernero J; Ohtsu A; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Ajani JA; Tomasek J; Safran H; Chandrawansa K; Hsu Y; Heathman M; Khan A; Ni L; Melemed AS; Gao L; Ferry D; Fuchs CS. 2017.Mol Cancer Ther.16: 2215-2222. IF:5,764
  • Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Jiménez-Fonseca P; Carmona-Bayonas A; Sánchez Lorenzo ML; Plazas JG; Custodio A; Hernández R; Garrido M; García T; Echavarría I; Cano JM; Rodríguez Palomo A; Mangas M; Macías Declara I; Ramchandani A; Visa L; Viudez A; Buxó E; Díaz-Serrano A; López C; Azkarate A; Longo F; Castañón E; Sánchez Bayona R; Pimentel P; Limón ML; Cerdá P; Álvarez Llosa R; Serrano R; Lobera MP; Alsina M; Hurtado Nuño A; Gómez-Martin C.2017.Gastric Cancer.20: 465-474. IF:5,454
  • Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J. 2017.Mol Oncol.11: 1263-1272. IF:5,314
  • Unveiling changes in the landscape of patient populations in cancer early drug development. Hierro C; Azaro A; Argilés G; Elez E; Gómez P; Carles J; Rodon J. 2017.Oncotarget.8: 14158-14172. IF:5,168
  • Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer. García-Carbonero R; van Cutsem E; Rivera F; Jassem J; Gore I; Tebbutt N; Braiteh F; Argiles G; Wainberg ZA; Funke R; Anderson M; McCall B; Stroh M; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Hurwitz H. 2017.Oncologist.22: 375-30. IF:4,962
  • Cell-Free DNA in metastatic colorectal cancer: A systematic review and Meta-Analysis. Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A. 2017.Oncologist.22: 1049-1055. IF:4,962
  • A phase ib dose-escalation study of the safety, tolerability, and pharmacokinetics of cobimetinib and duligotuzumab in patients with previously treated locally advanced ormetastatic cancers with mutant KRAS. Lieu CH; Hidalgo M; Berlin JD; Ko AH; Cervantes A; LoRusso P; Gerber DE; Eder JP; Eckhardt SG; Kapp AV; Tsuhako A; McCall B; Pirzkall A; Uyei A; Tabernero J. 2017.Oncologist.22: 1024-89. IF:4,962
  • Electronic tongues to assess wine sensory descriptors.Cetó X; González-Calabuig A; Crespo N; Pérez S; Capdevila J; Puig-Pujol A; Valle MD. 2017.Talanta.162: 218-224. IF:4,162
  • Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).Capdevila J; Trigo JM; Aller J; Manzano JL; Garcia-Adrian S; Zafon C; Reig O; Bohn U; Ramon Y Cajal T; Duran M; Gonzalez-Astorga B; Lopez-Alfonso A; Medina J; Porras I; Reina JJ; Palacios N; Grande E; Cillan E; Matos I; Grau JJ. 2017.Eur J Endocrinol.177: 309-317. IF:4,101
  • ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation..Knigge U; Capdevila J; Bartsch DK; Baudin E; Falkerby J; Kianmanesh R; Kos-Kudla B; Niederle B; Nieveen van Dijkum E; O’Toole D; Pascher A; Reed N; Sundin A; Vullierme MP; all other Antibes Consensus Conference Participants. 2017.Neuroendocrinology.105: 310-319. IF:3,608
  • ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Partelli S; Bartsch DK; Capdevila J; Chen J; Knigge U; Niederle B; Nieveen van Dijkum EJ; Pape UF; Pascher A; Ramage J; Reed N; Ruszniewski P; Scoazec JY; Toumpanakis C; Kianmanesh R; Falconi M; all other Antibes Consensus Conference participants. 2017.Neuroendocrinology.105: 255-265. IF:3,608
  • Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T. 2017.Invest New Drugs.35: 235-241. IF:3,484
  • A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Wainberg ZA; Alsina M; Soares HP; Braña I; Britten CD; Del Conte G; Ezeh P; Houk B; Kern KA; Leong S; Pathan N; Pierce KJ; Siu LL; Vermette J; Tabernero J. 2017.Target Oncol.12: 775-785. IF:3,438
  • The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J. 2017.Target Oncol.12: 757-774. IF:3,438
  • A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. Reynolds KL; Bedard PL; Lee SH; Lin CC; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham DM; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang YJ. 2017.BMC Cancer.17: 646-0. IF:3,288
  • Genetics of Pheochromocytomas and Paragangliomas: An Overview on the Recently Implicated Genes MERTK, MET, Fibroblast Growth Factor Receptor 1, and H3F3A. Toledo RA. 2017.Endocrinol Metab Clin North Am.46: 459-489. IF:3,204
  • Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma, Correlated with Liver Metastasis and Poor Prognosis. Salcedo Allende MT; Zeron-Medina J; Hernandez J; Macarulla T; Balsells J; Merino X; Allende H; Tabernero J; Ramon Y Cajal Agüeras S. 2017.Pancreas.46: 913-920. IF:2,967
  • Desmoid-Type Fibromatosis: Who, When, and How to Treat. Martínez Trufero J; Pajares Bernad I; Torres Ramón I; Hernando Cubero J; Pazo Cid R. 2017.Curr Treat Options Oncol.18: 29-0. IF:2,820
  • Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. O’Neil, B.H.; Wallmark, J.M.; Lorente, D.; Elez, E.; Raimbourg, J.; Gomez-Roca, C.; Ejadi, S.; Piha-Paul, S.A.; Stein, M.N.; Abdul Razak, A.R.; Dotti, K.; Santoro, A.; Cohen, R.B.; Gould, M.; Saraf, S.; Stein, K.; Han, S.-W.. 2017.PLoS One.IF:2,806
  • Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.Cohn AL; Yoshino T; Heinemann V; Obermannova R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia-Alfonso P; Portnoy DC; Van Cutsem E; Yamazaki K; Clingan PR; Polikoff J; Lonardi S; O’Brien LM; Gao L; Yang L; Ferry D; Nasroulah F; Tabernero J.2017.Cancer Chemother Pharmacol.80: 599-608. IF:2,737
  • Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting.Dómine Gómez, M.; Díaz Fernández, N.; Cantos Sánchez de Ibargüen, B.; Zugazabeitia Olabarría, L.; Martínez Lozano, J.; Poza de Celis, R.; Trujillo Vílchez, R.; Peláez Fernández, I.; Capdevila Castillón, J.; Traseira Lugilde, S.; Esteban González, E.. 2017.ADV THER.34: 136-147. IF:2,709
  • Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors..Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE). 2017.CURR ONCOL REP.19: 72-0. IF:2,608
  • Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. Jiménez-Fonseca P; Gómez Saez JM; Santamaria Sandi J; Capdevila J; Navarro Gonzalez E; Zafon Llopis C; Ramón Y Cajal Asensio T; Riesco-Eizaguirre G; Grande E; Galofré JC.2017.Clin Transl Oncol.19: 12-20. IF:2,353
  • Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R. 2017.Clin Transl Oncol.19: 227-235. IF:2,353
  • Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G. 2017.Clin Transl Oncol.19: 279-287. IF:2,353
  • Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Hidalgo M; Álvarez R; Gallego J; Guillén-Ponce C; Laquente B; Macarulla T; Muñoz A; Salgado M; Vera R; Adeva J; Alés I; Arévalo S; Blázquez J; Calsina A; Carmona A; de Madaria E; Díaz R; Díez L; Fernández T; de Paredes BG; Gallardo ME; González I; Hernando O; Jiménez P; López A; López C; López-Ríos F; Martín E; Martínez J; Martínez A; Montans J; Pazo R; Plaza JC; Peiró I; Reina JJ; Sanjuanbenito A; Yaya R; Carrato A. 2017.Clin Transl Oncol.19: 667-681. IF:2,353
  • Adjuvant treatment for pancreatic ductal carcinoma.Macarulla T; Fernández T; Gallardo ME; Hernando O; López AM; Hidalgo M. 2017.Clin Transl Oncol.19: 1199-1204. IF:2,353
  • Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience. Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J. 2017.FUTURE ONCOL.13: 615-624. IF:2,131
  • nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K. 2017.Onco Targets Ther.10: 591-596. IF:1,653
  • Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients.Hierro, Cinta; Alsina, Maria; Tabernero, Josep. 2017.TRANSL CANCER RES.6: 1035-1039. IF:1,167
  • Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. Garralda E; Dienstmann R; Tabernero J. 2017.Am Soc Clin Oncol Educ Book.37: 210-215.
  • The European Cancer Patient’s Bill of Rights, update and implementation 2016. Højgaard L; Löwenberg B; Selby P; Lawler M; Banks I; Law K; Albreht T; Armand JP; Barbacid M; Barzach M; Bergh J; Cameron D; Conte P; de Braud F; de Gramont A; De Lorenzo F; Diehl V; Diler S; Erdem S; Geissler J; Gore-Booth J; Henning G; Horgan D; Jassem J; Johnson P; Kaasa S; Kapitein P; Karjalainen S; Kelly J; Kienesberger A; La Vecchia C; Lacombe D; Lindahl T; Luzzatto L; Malby R; Mastris K; Meunier F; Murphy M; Naredi P; Nurse P; Oliver K; Pearce J; Pelouchov J; Piccart M; Pinedo B; Spurrier-Bernard G; Sullivan R; Tabernero J; Van de Velde C; van Herk B; Vedsted P; Waldmann A; Weller D; Wilking N; Wilson R; Yared W; Zielinski C; Zur Hausen H; Le Chevalier T; Johnston P. 2017.ESMO Open.
  • Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. Tabernero J; Vyas M; Giuliani R; Arnold D; Cardoso F; Casali PG; Cervantes A; Eggermont AM; Eniu A; Jassem J; Pentheroudakis G; Peters S; Rauh S; Zielinski CC; Stahel RA; Voest E; Douillard JY; McGregor K; Ciardiello F. 2017.ESMO Open.
  • Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)..Ricotta R; Verrioli A; Ghezzi S; Porcu L; Grothey A; Falcone A; Van Cutsem E; Argilés G; Adenis A; Ychou M; Barone C; Bouché O; Peeters M; Humblet Y; Mineur L; Sobrero AF; Hubbard JM; Cremolini C; Prenen H; Tabernero J; Jarraya H; Mazard T; Deguelte-Lardiere S; Papadimitriou K; Van den Eynde M; Pastorino A; Redaelli D; Bencardino K; Funaioli C; Amatu A; Carlo-Stella G; Torri V; Sartore-Bianchi A; Vanzulli A; Siena S. 2017.ESMO Open.
  • Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.Verdaguer H; Saurí T; Macarulla T. 2017.J Gastrointest Oncol.8: 405-417.
  • The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J. 2017.J Gastrointest Cancer.48: 135-147.
  • Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. Prager, Gerald; Argiles, Guillem.2017.ESMO Open.
  • Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. Dafni U; Karlis D; Pedeli X; Bogaerts J; Pentheroudakis G; Tabernero J; Zielinski CC; Piccart MJ; de Vries EGE; Latino NJ; Douillard JY; Cherny NI. 2017.ESMO Open.
  • Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J. 2017.ESMO Open.
  • QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. Tabernero J; Van Cutsem E; Ohtsu A; Amellal N; Cadour S; Fougeray R; Haffemayer B; Mayer RJ. 2017.ESMO Open.
  • Tabernero J, Salazar R. Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC. Nat Rev Clin Oncol. 2016 Aug;13(8):467-8.
  • Martínez-Cardús A, Moran S, Musulen E, Moutinho C, Manzano JL, Martinez-Balibrea E, Tierno M, Élez E, Landolfi S, Lorden P, Arribas C, Müller F, Bock C, Tabernero J, Esteller M. Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology. 2016 Nov;151(5):961-972.
  • Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M. Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburgeffect. Nat Commun. 2016 Nov 2;7:13467.
  • Alsina M, Hierro C, Tabernero J. Antiangiogenic therapies in gastric cancer: trusting the pathway. Ann Oncol. 2016 Dec;27(12):2141-2143.
  • Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D13, McGovern D14, Lu B14, Ko A14.CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr;27(4):654-60.
  • Sartore-Bianchi A, Loupakis F, Argilés G, Prager GW. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol. 2016 Aug;27(8):1456-66.
  • Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1378-81.
  • Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO GlobalCurriculum Working Group. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. Ann Oncol. 2016 Aug;27(8):1557-65.
  • Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol. 2016 Apr;27(4):648-53.
  • Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD. Positron emission tomography response evaluation from a randomized phase III trial of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastaticadenocarcinoma of the pancreas. Ann Oncol. 2016 Nov;27(11):2082-2090.
  • Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Clin Cancer Res. 2016 Feb 1;22(3):644-56.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Jul 1;22(13):3260-7.
  • Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab ResistanceMediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clin Cancer Res. 2016 Jul 1;22(13):3260-7
  • Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-MutantColorectal Cancer. Cancer Res. 2016 Aug 1;76(15):4504-15.
  • Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene. 2016 Dec 15;35(50):6403-6415.
  • Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene. 2016 Sep 19. doi: 10.1038/onc.2016.316. [Epub ahead of print]
  • Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016 Jan;52:85-91
  • Prat A, Gilabert A, Puig-Peiro R, Feliu A, Riba M, Mangues MA, Tabernero J. Letter to the editor regarding the paper by A. Lozano Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom. Eur J Cancer. 2016 Nov;67:55-56.
  • Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Mol Cancer Ther. 2016 May;15(5):1106-12.
  • Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 Oct 11;115(8):974-982.
  • Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer. 2016 Feb 16;114(4):372-80.
  • Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016 Oct 25;115(9):e13.
  • Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109.
  • Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locallyadvanced rectal cancer patients. Carcinogenesis. 2016 Sep;37(9):852-7.
  • Ciardiello F, Adams R, Tabernero J, Seufferlein T, Taieb J, Moiseyenko V, Ma B, Lopez G, Vansteenkiste JF, Esser R, Tejpar S. Awareness, Understandingand Adoption of Precision Medicine to Deliver PersonalizedTreatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist. 2016 Mar;21(3):292-300.
  • Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016 Mar;23(3):191-9.
  • Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016 May;8(3):230-42.
  • Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016 Jun;81(6):1124-33.
  • Dienstmann R, Tabernero J. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. Cancer J. 2016 May-Jun;22(3):149-55.
  • Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J. Current and advancing treatments for metastatic colorectal cancer. Expert Opin Biol Ther. 2016;16(1):93-110.
  • Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer. 2016 May 31;16:339.
  • Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxisprogram. BMC Cancer. 2016 Nov 7;16(1):858.
  • Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400.
  • Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAFV600-Mutated Advanced Solid Tumors. Target Oncol. 2016 Apr;11(2):149-56.
  • Alsina M1,2,3, Moehler M4, Hierro C5,6, Guardeño R7, Tabernero J5,6. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Target Oncol. 2016 Aug;11(4):469-77.
  • Van Cutsem E, Yoshino T, Hocke J, Oum’Hamed Z, Studeny M4, Tabernero J. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus BestSupportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1.
  • Manchon-Walsh P, Aliste L, Espinàs JA, Prades J, Guarga A, Balart J, Biondo S, Castells A, Sanjuan X, Tabernero J, Borras JM; Catalonian Rectal Cancer Group.Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment. Eur J Surg Oncol. 2016 Dec;42(12):1873-1880.
  • Petty R, Anthoney A, Metges JP, Alsina M, Gonçalves A, Brown J, Montagut C, Gunzer K, Laus G, Iglesias Dios JL, Miguel-Lillo B, Bohan P, Salazar R. Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Cancer Chemother Pharmacol. 2016 Apr;77(4):819-27.
  • Garcia-Carbonero R1, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O’Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186-94.
  • Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J, Krenning E, Reed N, O’Toole D; Vienna Consensus Conference participants. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding GobletCell Carcinomas). Neuroendocrinology. 2016;103(2):144-52.
  • Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103(2):119-24.
  • Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J, O’Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125-38.
  • Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown PrimarySite. Neuroendocrinology. 2016;103(2):172-85.
  • Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional PancreaticNeuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-71.
  • Matos I, Elez E, Capdevila J, Tabernero J. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opin Emerg Drugs. 2016 Sep;21(3):267-82.
  • Grande E, Santamaría Sandi J, Capdevila J, Navarro González E, Zafón Llopis C, Ramón Y Cajal Asensio T, Gómez Sáez JM, Jiménez-Fonseca P, Riesco-Eizaguirre G, Galofré JC. Consensus on management of advanced medullary thyroid carcinoma on behalf of the WorkingGroup of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish TaskForce Group for Orphan and Infrequent Tumors (GETHI). Clin Transl Oncol. 2016 Aug;18(8):769-75.
  • Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1172-1178.
  • Jiménez-Fonseca P, Gómez Saez JM, Santamaria Sandi J, Capdevila J, Navarro Gonzalez E, Zafon Llopis C, Ramón Y Cajal Asensio T, Riesco-Eizaguirre G, Grande E, Galofré JC. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. Clin Transl Oncol. 2017 Jan;19(1):12-20.
  • Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced PancreaticNeuroendocrine Tumours. Anticancer Res. 2016 Feb;36(2):713-9.
  • Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. [Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. [Article in Spanish] Med Clin (Barc). 2016 Jun 3;146(11):511.e1-511.e22.
  • Massuti B, Sanchez JM, Hernando-Trancho F, Karachaliou N, Rosell R. Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?. Transl Lung Cancer Res. 2013 Jun;2(3):208-21.
  • Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J , De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for MedicalOncology (ESMO). ESMO Open. 2016 Dec 7;1(6):e000107.
  • Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016 Jun;7(3):469-78.
  • Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG. ESMO Magnitude of Clinical Benefit Scale V.1.0 questions and answers. ESMO Open. 2016 Oct 18;1(5):e000100.
  • Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016 Sep 29;1(5):e000097.
  • Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Demonty G, Hechmati G, Douillard JY. Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectalcarcinoma: results from a randomised controlled trial. ESMO Open. 2016 Mar 31;1(2):e000041.
  • Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016 Jan 14:1-11.
  • Riesco-Eizaguirre G, Galofré JC, Grande E, Zafón Llopis C, Ramón y Cajal Asensio T, Navarro González E, Jiménez-Fonseca P, Santamaría Sandi J, Gómez Sáez JM, Capdevila J. Spanish consensus for the management of patients with advanced radioactive iodine refractorydifferentiated thyroid cancer. Endocrinol Nutr. 2016 Apr;63(4):e17-24.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG.  Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Kubicka S.  [Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial].Strahlenther Onkol 2016 Jul; 192(7): 505-6
  • Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.  First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol 2016 Apr; 11(2): 149-56
  • Dienstmann R, Rodón J, Tabernero J.  Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 2015 May; 9(5): 940-50
  • Alsina M, Landolfi S, Aura C, Caci K, Jimenez J, Prudkin L, Castro S, Moreno D, Navalpotro B, Tabernero J, Scaltriti M.  Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann. Oncol. 2015 Feb; 26(2): 438-9
  • Elez E, Kocákova I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Šmakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann. Oncol. 2015 Jan; 26(1): 132-40
  • Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C.  A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 2015 Feb; 21(4): 730-8
  • Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug; 16(8): 937-48
  • Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argiles G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.  Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov 2015 Jun; 5(6): 598-609
  • Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May; 16(5): 499-508
  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 2015 May; 372(20): 1909-19
  • Hierro C, Rodón J, Tabernero J.  Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin. Oncol. 2015 Dec; 42(6): 801-19
  • Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martinez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.  Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nat. Med. 2015 Jul; 21(7): 741-50
  • Tabernero J.  Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no ‘sweetheart’ solution. Ann. Oncol. 2015 Aug; 26(8): 1529-31
  • Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzén F, Veronese ML, Tabernero J, Baselga J.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N. Engl. J. Med. 2015 Aug; 373(8): 726-36
  • Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.  The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015 Nov; 21(11): 1350-6
  • Tabernero J, Takayuki Y, Cohn AL.  Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 Jun; 16(6): e262
  • Ugalde-Olano A, Egia A, Fernández-Ruiz S, Loizaga-Iriarte A, Zuñiga-García P, Garcia S, Royo F, Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martín-Martín N, Arruabarrena-Aristorena A, Torrano-Moya V, Valcárcel-Jiménez L, Sánchez-Mosquera P, Caro-Maldonado A, González-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernández S, Arrieta E, Zorroza K, Castillo-Martín M, Serra V, Salazar E, Macías-Cámara N, Tabernero J, Baselga J, Cordon-Cardo C, Aransay AM, Villar AD, Iovanna JL, Falcón-Pérez JM, Unda M, Bilbao R, Carracedo A.  Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods 2015 May; 77-78: 25-30
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.  MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J.  Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE 2015; 10(6): e0129876
  • Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martínez-Sáez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov 2015 Nov; 5(11): 1164-77
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
  • André T, De Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J. Clin. Oncol. 2015 Dec; 33(35): 4176-87
  • Dienstmann R, Salazar R, Tabernero J.  Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J. Clin. Oncol. 2015 Jun; 33(16): 1787-96
  • Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodón J, Peddareddigari V, Luo FR, Soria JC.  Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J. Clin. Oncol. 2015 Oct; 33(30): 3401-8
  • Venook AP, Tabernero J.  Progression-free survival: helpful biomarker or clinically meaningless end point?J. Clin. Oncol. 2015 Jan; 33(1): 4-6
  • Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.  FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut 2015 Jun; 64(6): 921-8
  • De Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, Hamilton SR.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015 Apr; 12(4): 197-212
  • Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ.  A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J. Natl. Cancer Inst. 2015 Dec; 107(12): djv258
  • Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J. Natl. Cancer Inst. 2015 Feb; 107(2)
  • Gupta S, Argiles G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA.  A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin. Cancer Res. 2015 Dec; 21(23): 5235-44
  • Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A.  Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.Clin. Cancer Res. 2015 Jul; 21(14): 3307-17
  • Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Braña I, Tabernero J.  First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin. Cancer Res. 2015 Apr; 21(8): 1888-95
  • Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.  Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin. Cancer Res. 2015 Jun; 21(11): 2462-70
  • Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, Garcia-Carbonero R, Aller J, Capdevila J, Grande E.  Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015 Sep; 34(3): 381-400
  • Garcia-Carbonero R, García-Figueiras R, Carmona-Bayonas A, Sevilla I, Teulé A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jiménez-Fonseca P.  Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015 Dec; 34(4): 823-42
  • Van Cutsem E, Prenen H, D’Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, Oum’Hamed Z, Dressler H, Studeny M, Capdevila J.  A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Ann. Oncol. 2015 Oct; 26(10): 2085-91
  • Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P.  Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann. Oncol. 2015 Jan; 26(1): 149-56
  • Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez de Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.  Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Ann. Oncol. 2015 Sep; 26(9): 1936-41
  • Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Gravalos C, Escudero P, Vera R, Aranda E, Garcia-Alfonso P, Gallego-Plazas J, López C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Diaz-Rubio E.  Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann. Oncol. 2015 Mar; 26(3): 535-41
  • Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J.  Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur. J. Cancer 2015 Jul; 51(10): 1231-42
  • Argiles G, Saunders MP, Rivera F, Sobrero A, Benson A, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.  Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur. J. Cancer 2015 May; 51(8): 942-9
  • Piha-Paul SA, Munster PN, Hollebecque A, Argiles G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S.  Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur. J. Cancer 2015 Sep; 51(14): 1865-73
  • Ruff P, Ferry DR, Lakomy R, Prausová J, van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E.  Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur. J. Cancer 2015 Jan; 51(1): 18-26
  • Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellá G, Salazar R.  Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist 2015 Feb; 20(2): 127-33
  • Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.  Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Br. J. Cancer 2015 Jun; 112(12): 1874-81
  • Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Gravalos C, Biondo S, Palacios A, Aranda E. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 2015; 15: 60
  • Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura A, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P.  Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer 2015; 15: 495
  • Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R.  Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas 2015 Mar; 44(2): 181-9
  • Papadopoulos KP, Egile C, Ruiz-Soto R, Jiang J, Shi W, Bentzien F, Rasco D, Abrisqueta P, Vose JM, Tabernero J.  Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk. Lymphoma 2015 Jun; 56(6): 1763-70
  • Sanz-Garcia E, Saurí T, Tabernero J, Macarulla T.  Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2015 Jun; 11(6): 995-1004
  • Elez E, Argiles G, Tabernero J.  First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Curr Treat Options Oncol 2015 Nov; 16(11): 52
  • Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O’Connor JM, Raymond E.  Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother. Pharmacol. 2015 Jun; 75(6): 1099-114
  • Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J.  Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 2015 Dec; 17(12): 982-7
  • Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F.  Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Rev Pharmacoecon Outcomes Res 2015; 15(4): 579-89
  • Dienstmann R, Salazar R, Tabernero J.  Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. Am Soc Clin Oncol Educ Book 2015; : e149-56
  • Dienstmann R, Salazar R, Tabernero J.  Genomic testing in colorectal cancer: how much is enough?Oncology (Williston Park, N.Y.) 2015 Mar; 29(3): 186-8
  • Pedersen K, Canals F, Prat A, Tabernero J, Arribas J.  PELO negatively regulates HER receptor signalling and metastasis. Oncogene 2014 Feb; 33(9): 1190-7
  • Ordóñez-Morán P, Irmisch A, Barbáchano A, Chicote I, Tenbaum S, Landolfi S, Tabernero J, Huelsken J, Muñoz A, Pálmer HG.  SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. Oncogene 2014 Apr; 33(15): 1975-85
  • Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J.  Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
  • Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014 Jan; 383(9911): 31-9
  • Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capellá G, Salazar R, Orphanides G, Wessels LF, Bernards R, Simon IM.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 2014 Feb; 134(3): 552-62
  • Moutinho C, Martinez-Cardús A, Santos C, Navarro-Pérez V, Martínez-Balibrea E, Musulen E, Carmona FJ, Sartore-Bianchi A, Cassingena A, Siena S, Elez E, Tabernero J, Salazar R, Abad A, Esteller M.  Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J. Natl. Cancer Inst. 2014 Jan; 106(1): djt322
  • Tabernero J, Van Cutsem E, Lakomy R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ.  Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer 2014 Jan; 50(2): 320-31
  • Delord JP, Tabernero J, Garcia-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC.  Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur. J. Cancer 2014 Feb; 50(3): 496-505
  • Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J.  Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Clin. Cancer Res. 2014 Aug; 20(16): 4240-50
  • Soria JC, Debraud F, Bahleda R, Adamo B, André F, Dienstmann R, Dientsmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D’Incalci M, Zucchetti M, Camboni MG, Tabernero J.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann. Oncol. 2014 Nov; 25(11): 2244-51
  • Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J.  A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin. Cancer Res. 2014 May; 20(10): 2793-804
  • Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ.  First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin. Cancer Res. 2014 Apr; 20(8): 2205-14
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J.  Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
  • Rodrigues P, Macaya I, Bazzocco S, Mazzolini R, Andretta E, Dopeso H, Mateo-Lozano S, Bilić J, Cartón-García F, Nieto R, Suárez-López L, Afonso E, Landolfi S, Hernandez-Losa J, Kobayashi K, Cajal SR, Tabernero J, Tebbutt NC, Mariadason JM, Schwartz S, Arango D.  RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Nat Commun 2014; 5: 5458
  • Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann. Oncol. 2014 Dec; 25(12): 2378-85
  • Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L.  Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur. J. Cancer 2014 Nov; 50(17): 2983-93
  • Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.  Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. Clin. Cancer Res. 2014 Nov; 20(22): 5663-71
  • Caplin ME, Pavel M, Ruszniewski P.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N. Engl. J. Med. 2014 Oct; 371(16): 1556-7
  • Sclafani F, González D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.  TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J. Natl. Cancer Inst. 2014 Jul; 106(7)
  • Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Jul; 15(8): 862-73
  • Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M.  Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol. Cancer 2014; 13: 141
  • Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardús A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martínez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M.  A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat Commun 2014; 5: 3608
  • Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, LoRusso PM.  Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2014 May; 20(9): 2445-56
  • Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, Van Laethem JL, Ottensmeier C, López-Martín JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.  A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2014 Apr; 20(8): 2192-204
  • Dienstmann R, Rodón J, Serra V, Tabernero J.  Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther. 2014 May; 13(5): 1021-31
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 2014 Sep; 25(9): 1729-35
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013 Jul; 10(7): 377-89
  • Rodón J, Dienstmann R, Serra V, Tabernero J.  Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013 Mar; 10(3): 143-53
  • Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, Guzman M, Sampath D, Nannini M, Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C, Roda D, Cervantes A, Tabernero J, Patel P, Baselga J.  Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin. Cancer Res. 2013 Dec; 19(24): 6976-86
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J.  Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
  • Dienstmann R, Rodón J, Barretina J, Tabernero J.  Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol. 2013 May; 31(15): 1874-84
  • Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argiles G, Vivancos A, Tabernero J, Rojas S, Pálmer HG.  A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res. 2013 Dec; 19(24): 6787-801
  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013 Oct; 369(18): 1691-703
  • Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013 Sep; 369(11): 1023-34
  • Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.  A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann. Oncol. 2013 Jul; 24(7): 1777-85
  • Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013 Jan; 381(9863): 303-12
  • Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van’t Veer L, Salazar R, Bernards R, Capellá G.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013 Apr; 62(4): 540-9
  • Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E.  Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br. J. Cancer 2013 Oct; 109(7): 1735-43
  • Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013 Apr; 3(4): 406-17
  • Vilar E, Tabernero J.  Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov 2013 May; 3(5): 502-11
  • Eskens FA, Ramos FJ, Burger H, O’Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J.  Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 2013 Nov; 19(22): 6296-304
  • Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS.  Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin. Cancer Res. 2013 Jul; 19(14): 3987-95
  • Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O’Dwyer PJ.  Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin. Cancer Res. 2013 May; 19(9): 2541-50
  • De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J.  The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. Cancer Metastasis Rev. 2013 Dec; 32(3): 465-77
  • Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C, Tabernero J, Coronado C, García M, Soto Matos-Pita A, Miguel-Lillo B, Cullell-Young M, Iglesias Dios JL, Paz-Ares L.  Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013 Jul; 72(1): 75-83
  • Van Cutsem E, Borras JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J. Improving outcomes in colorectal cancer: where do we go from here? Eur. J. Cancer 2013 Jul; 49(11): 2476-85
  • Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit. Rev. Oncol. Hematol. 2013 Feb; 85(2): 121-35
  • Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18(9): 1004-12
  • Simó R, Plana-Ripoll O, Puente D, Morros R, Mundet X, Vilca LM, Hernández C, Fuentes I, Procupet A, Tabernero JM, Violán C.  Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The barcelona case-control study. PLoS ONE 2013; 8(11): e79968
  • Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J.  Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS ONE 2013; 8(11): e62264
  • Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Carreras MJ, Coronado C, Kahatt C, Soto Matos-Pita A, Fernandez Teruel C, Siguero M, Cullell-Young M, Tabernero J.  A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013 May; 71(5): 1247-54
  • Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabemero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I.  HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab Ann Oncol. 2013; 24: 3123-3128
  • Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, De Gramont A, Yeh CG.  A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013; 24: 1567-1573
  • Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Pálmer HG.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 2012 Jun; 18(6): 892-901
  • Dienstmann R, De Dosso S, Felip E, Tabernero J.  Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012 Feb; 6(1): 15-26
  • Dienstmann R, Serpico D, Rodón J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Pérez-García J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernandez-Losa J, Vivancos A, Tabernero J. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 2012 Sep; 11(9): 2062-71
  • García-García C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.  Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 2012 May; 18(9): 2603-12
  • Serrano C, Cortes J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.  Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann. Oncol. 2012 Apr; 23(4): 897-902
  • Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J.  A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs 2012 Feb; 30(1): 299-305
  • Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2012 Sep; 18(17): 4764-74
  • Argiles G, Dienstmann R, Elez E, Tabernero J.  Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol 2012 Apr; 8(4): 373-89
  • Vilar E, Tabernero J.  Cancer: Pinprick diagnostics. Nature 2012 Jun; 486(7404): 482-3
  • De Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.Lancet Oncol. 2012 Dec; 13(12): 1225-33
  • De Mattos-Arruda L, Tabernero J, Seoane J, Cortes J.  Circulating tumour cells in early breast cancer.Lancet Oncol. 2012 Sep; 13(9): e370; author reply e370
  • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012 Oct; 30(28): 3499-506
  • Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, De Gramont A.  Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J. Clin. Oncol. 2012 Sep; 30(27): 3353-60
  • Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J. Clin. Oncol. 2012 May; 30(14): 1620-7
  • Olmos D, A’hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.  Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J. Clin. Oncol. 2012 Mar; 30(9): 996-1004
  • Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak O, Hackl W, Baselga J.  Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 2012 Sep; 23(9): 2399-408
  • Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 2012 Oct; 23(10): 2479-516
  • Starling N, Vázquez-Mazón F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, Ruiz-Garcia A, Wei G, Tursi JM, Guillén-Ponce C, Carrato A.  A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann. Oncol. 2012 Jan; 23(1): 119-27
  • Diaz-Rubio E, Gomez-España A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallen M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17(1): 15-25
  • Sastre J, Maestro ML, Gomez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallen M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Diaz-Rubio E.  Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012; 17(7): 947-55
  • Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH.  Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin. Cancer Res. 2012 Nov; 18(22): 6364-72
  • Yap TA, Cortés-Funes H, Shaw H, Rodríguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martín JA.  First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br. J. Cancer 2012 Apr; 106(8): 1379-85
  • Diaz-Rubio E, Gomez-España A, Massuti B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E.  Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS ONE 2012; 7(10): e47345
  • Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, Massard C, Kaye S.  Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants – reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. Eur. J. Cancer 2012 Mar; 48(4): 594-6
  • Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.Genome Res. 2012 Feb; 22(2): 292-8
  • Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J.  Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012 Jun; 9(6): 359-66
  • Grande E, Capdevila J, Barriuso J, Antón-Aparicio L, Castellano D.  Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? Cancer Metastasis Rev. 2012 Jun; 31(1): 47-53
  • Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernandez-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S, Aaltonen LA, Mooseker MS, Arango D.  Brush border myosin Ia has tumor suppressor activity in the intestine. Proc. Natl. Acad. Sci. U.S.A. 2012 Jan; 109(5): 1530-5
  • Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H.  Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther 2012 Sep; 12(9): 1137-47
  • Argiles G, Rodón J, Tabernero J.  Depicting the evolving scenario of translational-guided drug development. Clin Transl Oncol 2012 Dec; 14(12): 881-2
  • Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massuti B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E.  Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. Cancer Chemother. Pharmacol. 2011 Jan; 67(1): 75-82
  • Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, DePinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M.  Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 2011 Oct; 43(10): 964-8
  • Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J.  Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2011 Oct; 29(28): 3783-90
  • Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, del Rio M, Gongora C.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 2011 Feb; 71(3): 1041-9
  • Bouchahda M, Macarulla T, Liedo G, Levi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med. Oncol. 2011 Dec; 28 Suppl 1: S253-8
  • Vilar E, Pérez-García J, Tabernero J.  Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther. 2011 Mar; 10(3): 395-403
  • Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Roselló S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res. 2011 Feb; 71(3): 675-85
  • Dienstmann R, Tabernero J.  BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011 Mar; 11(3): 285-95
  • Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol. 2011 Apr; 29(11): 1465-71
  • Dienstmann R, Rodón J, Markman B, Tabernero J.  Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov 2011 May; 6(2): 210-36
  • De Mattos-Arruda L, Dienstmann R, Tabernero J.  Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer 2011 Dec; 10(4): 279-89
  • Gómez-Martín C, Hidalgo M, Tabernero J, Isla D.  SEOM clinical guidelines for the treatment of pancreatic cancer. Clin Transl Oncol 2011 Aug; 13(8): 528-35
  • Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Diaz-Rubio E.  Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011 Mar; 13(3): 162-78
  • Tabernero J, Dirix L, Schöffski P, Cervantes A, López-Martín JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH.  A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 2011 Oct; 17(19): 6313-21
  • Vilar E, Tabernero J, Gruber SB.  Micromanaging the classification of colon cancer: the role of the microRNAome. Clin. Cancer Res. 2011 Dec; 17(23): 7207-9
  • De Mattos-Arruda L, Olmos D, Tabernero J.  Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol 2011 Dec; 7(12): 1385-97
  • Dienstmann R, Braña I, Rodón J, Tabernero J.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011; 16(12): 1729-40
  • Capdevila J, Tabernero J.  A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Cancer Discov 2011 Aug; 1(3): 213-21
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010 Feb; 463(7283): 899-905
  • Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F.  Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J. Clin. Oncol. 2010 Mar; 28(7): 1181-9
  • Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A.  Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann. Oncol. 2010 Jul; 21(7): 1537-45
  • Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J.  Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol. 2010 Apr; 21(4): 683-91
  • De Gramont A, Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL.  Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J. Clin. Oncol. 2010 Feb; 28(4): 527-30
  • Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J.  Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann. Oncol. 2010 Feb; 21(2): 195-8
  • Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernandez-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramón y Cajal S, Tabernero J, Schwartz S, Arango D.  Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin. Cancer Res. 2010 Apr; 16(8): 2375-82
  • Elez E, Alsina M, Tabernero J.  Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. Cancer Treat. Rev. 2010 Feb; 36 Suppl 1: S15-6
  • Capdevila J, Argiles G, Rodriguez-Frexinos V, Nuñez I, Tabernero J.  New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov Med 2010 Feb; 9(45): 153-62
  • Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E.  Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer–an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann. Oncol. 2010 Aug; 21(8): 1579-84
  • Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Glynne Jones R, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J.  Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann. Oncol. 2010 Jun; 21 Suppl 6: vi1-10
  • Serrano C, Markman B, Tabernero J.  Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. Cancer J 2010; 16(3): 226-34
  • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010 Aug; 11(8): 753-62
  • Markman B, Javier Ramos F, Capdevila J, Tabernero J.  EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51: 71-119
  • Brana I, Tabernero J.  Cardiotoxicity. Ann. Oncol. 2010 Oct; 21 Suppl 7: vii173-9
  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010 Nov; 28(31): 4697-705
  • Dienstmann R, Tabernero J.  Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 2010 Dec; 11(12): 1434-41
  • Markman B, Dienstmann R, Tabernero J.  Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs.Oncotarget 2010 Nov; 1(7): 530-43
  • Markman B, Tabernero J.  Monoclonal antibodies in solid tumours. Curr Clin Pharmacol 2010 Aug; 5(3): 160-5
  • Markman B, Rodríguez-Freixinos V, Tabernero J.  Biomarkers in colorectal cancer. Clin Transl Oncol 2010 Apr; 12(4): 261-70
  • Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 2009 Aug; 41(8): 882-4
  • Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massuti B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E.  Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.Int. J. Radiat. Oncol. Biol. Phys. 2009 Dec; 75(5): 1430-6
  • Goldberg RM, Meropol NJ, Tabernero J.  Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res 2009 Sep; 3(5): S23-7
  • Capdevila J, Pérez-García J, Obiols G, Tabernero J.  Targeted therapies in thyroid cancer. Target Oncol 2009 Dec; 4(4): 275-85
  • Tabernero J, Macarulla T.  Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J. Clin. Oncol. 2009 Nov; 27(33): 5487-91
  • Macarulla T, Capdevila J, Pérez-García J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J.  New approaches and targets in advanced colorectal cancer. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 79-88
  • Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C.  The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann. Oncol. 2009 Jun; 20 Suppl 7: vii1-vii6
  • André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, De Gramont A.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009 Jul; 27(19): 3109-16
  • Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 2009 Jul; 27(19): 3117-25
  • Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Diaz-Rubio E.  Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009 May; 11(5): 290-301
  • Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Pérez-García J, Tabernero J.  Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Curr Opin Oncol 2009 Jul; 21(4): 374-80
  • Schöffski P, Guillem V, García M, Rivera F, Tabernero J, Cullell M, López-Martín JA, Pollard P, Dumez H, del Muro XG, Paz-Ares L.  Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs 2009; 7(1): 57-70
  • Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev. 2009 Jun; 35(4): 354-63
  • Sastre J, Aranda E, Massuti B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B, Gomez-España A, González-Flores E, Rivera F, Losa F, Garcia T, Sanchez-Rovira P, Maestu I, Diaz-Rubio E.  Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit. Rev. Oncol. Hematol. 2009 May; 70(2): 134-44
  • Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J.  The role of salvage treatment in advanced colorectal cancer. Crit. Rev. Oncol. Hematol. 2009 Jul; 71(1): 53-61
  • Capdevila J, Salazar R.  Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors Target Oncol 2009 Dec; 4(4): 287-296
  • Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J.  The role of salvage treatment in advanced colorectal cancer 2009;
  • Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 2009 Jun; 20(6): 985-92
  • Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, Hofheinz RD.  Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009 Jul; 20(6): 519-24
  • Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.  Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009; 15(5): 406-20
  • Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martín M.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 2007 Aug; 25(23): 3399-406